Oral antifungal medication for fungal nail infections

References

Citations

1. Schlefman BS (1999). Onychomycosis: A compendium of facts and a clinical experience. Journal of Foot and Ankle Surgery, 38(4): 290–302.

2. Rodgers P, Bassler M (2001). Treating onychomycosis. American Family Physician, 63(4): 663–672.

3. Darkes MJM, et al. (2003). Terbinafine, a review of its use in onychomycosis in adults. American Journal of Clinical Dermatology, 4(1): 39–65.

4. Nelson NM, et al. (2003). Tinea pedis and tinea manuum subsection of Superficial fungal infection: Dermatophytosis, tinea nigra, piedra. In IM Freedberg et al., eds., Fitzpatrick's Dermatology in General Medicine, 6th ed., vol. 2, pp. 1999–2001. New York: McGraw-Hill.

5. U.S. Food and Drug Administration (2001). FDA issues health advisory regarding the safety of Sporanox products and Lamisil tablets to treat fungal nail infections. FDA Talk Paper T01-22. Available online: http://www.fda.gov/bbs/topics/answers/2001/ans01083.html.

6. Gupta AK, et al. (2001). Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Journal of the American Academy of Dermatology, 44(3): 479–484.

Author:	Sabra L. Katz-Wise	Last Updated: August 23, 2006
Medical Review:	Patrice Burgess, MD - Family Medicine Randall D. Burr, MD - Dermatology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.